H1 2023 Financial Highlights

Rare Disease Key ongoing clinical-trial highlights TRIAL POPULATION PATIENTS DESIGN Palovarotene MOVE Phase III FOP (chronic) 107 NCT03312634 Fidrisertib FALKON Phase II NCT05039515 IPSEN Innovation for patient care PRIMARY ENDPOINT(S) STATUS Palovarotene - 5mg QD and upon flare-up, 20mg QD for 28 days, followed by 10mg for 56 days Annualized change in new HO volume U.S. PDUFA date: 16 August 2023 Placebo or FOP (chronic) 00 90 two dosing regimens Annualized change in new HO volume and safety of fidrisertib First patient commenced dosing Q1 2022 FOP: fibrodysplasia ossificans progressiva; QD: once a day; HO: heterotopic ossification; P DUFA: Prescription Drug User Fee Act. 29 29

View entire presentation